Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction. Pluripotent stem cells can be generated from the somatic cells of humans and are a useful model to study disease. Here, pluripotent stem cells are made from a patient with familial Parkinson's disease, and the resulting neurons exhibit elevated levels of α-synuclein, recapitulating the molecular features of the patient's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Efficient Derivation of Functional Floor Plate Tissue from Human Embryonic Stem Cells
Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J., & Studer, L. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.001 · Cited by 209 · cited 1×
“The dual SMAD inhibition protocol has been employed to generate floor plate tissue from human ESC”
MethodRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“A potential solution is to utilize reprogamming technology to generate disease-specific induced pluripotent stem cells (iPSCs”
BackgroundAnalyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“Results were normalized to human TBP using the comparative C(T) metho”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“Directed differentiation to dopaminergic neurons We used a feeder-free monolayer culture method of inducing neural differentiation under defined conditions, via dual inhibition of SMAD signallin”
Method
Cited by
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Genetics of Parkinson's Disease
Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,358
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Shi, Y., Kirwan, P., & Livesey, F. J. (2012) · Nature Protocols · doi:10.1038/nprot.2012.116 · Cited by 972
Induced Pluripotent Stem Cells: Past, Present, and Future
Yamanaka, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.005 · Cited by 843
“…iPSCs can be used to recapitulate phenotypes of not only monogenic diseases but also late-onset polygenic diseases, such as Parkinson’s disease (Devine et al., 2011), Alzheimer’s disease (Israel et al., 2012; Yagi et al., 2011; Yahata et al., 2011), and schizophrenia (Brennand et al., 2011).”
Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers
Fusco, G., Chen, S. W., Williamson, P. T. F., Cascella, R., Perni, M., Jarvis, J. A., Cecchi, C., Vendruscolo, M., Chiti, F., Cremades, N., et al. (2017) · Science · doi:10.1126/science.aan6160 · Cited by 673
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
The Synucleinopathies: Twenty Years On
Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179005 · Cited by 569
Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications
Liu, G., David, B. T., Trawczynski, M., & Fessler, R. G. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09935-x · Cited by 519
Ludtmann, M. H. R., Angelova, P. R., Horrocks, M. H., Choi, M. L., Rodrigues, M., Baev, A. Y., Berezhnov, A. V., Yao, Z., Little, D., Banushi, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04422-2 · Cited by 513
Self-citationPhysicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs)
Theillet, F.-X., Binolfi, A., Frembgen-Kesner, T., Hingorani, K., Sarkar, M., Kyne, C., Li, C., Crowley, P. B., Gierasch, L., Pielak, G. J., et al. (2014) · Chemical Reviews · doi:10.1021/cr400695p · Cited by 503
Induced pluripotent stem cells: the new patient?
Bellin, M., Marchetto, M. C., Gage, F. H., & Mummery, C. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3448 · Cited by 431
Singh, V. K., Kalsan, M., Kumar, N., Saini, A., & Chandra, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00002 · Cited by 416
“These iPSCs were then directed to differentiate into dopaminergic neurons in vitro for the study of PD (Devine et al., 2011).”
BackgroundHistorical Perspective: Models of Parkinson’s Disease
Chia, S. J., Tan, E.-K., & Chao, Y.-X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072464 · Cited by 401
Imaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N., Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S., et al. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-35 · Cited by 380
“The PCR conditions used have been previously described [2,42].”
MethodResultPaillusson, S., Gomez-Suaga, P., Stoica, R., Little, D., Gissen, P., Devine, M. J., Noble, W., Hanger, D. P., & Miller, C. C. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1704-z · Cited by 360
Self-citationInduced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 368
Deas, E., Cremades, N., Angelova, P. R., Ludtmann, M. H. R., Yao, Z., Chen, S., Horrocks, M. H., Banushi, B., Little, D., Devine, M. J., et al. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6343 · Cited by 360
Self-citationOtani, T., Marchetto, M. C., Gage, F. H., Simons, B. D., & Livesey, F. J. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.03.003 · Cited by 353
“2 iPSCs [Israel et al., 2012]; and NAS6 iPSCs [Devine et al., 2011]), chimpanzee iPSCs (chimp 00818 iPSCs and 01029 iPSCs [Marchetto et al., 2013]), and macaque ESCs (MF1 ESCs, MF12 ESCs, and MN1 ESCs from E. Curnow, Washington National Primate Research Centre) were cultured either with…”
MethodOrgan-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
The future of stem cell therapies for Parkinson disease
Parmar, M., Grealish, S., & Henchcliffe, C. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0257-7 · Cited by 306
How to make a midbrain dopaminergic neuron
Arenas, E., Denham, M., & Villaescusa, J. C. (2015) · Development · doi:10.1242/dev.097394 · Cited by 308
Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation
Angelova, P. R., Choi, M. L., Berezhnov, A. V., Horrocks, M. H., Hughes, C. D., De, S., Rodrigues, M., Yapom, R., Little, D., Dolt, K. S., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0542-z · Cited by 296
Self-citationIn vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 290
“…Lotharius et al., 2005; Van Vliet et al., 2008; Zhang et al., 2014; Smirnova et al., 2016; Harischandra et al., 2019; Taylor-Whiteley et al., 2019 Devine et al., 2011; Nguyen et al., 2011; Ryan et al., 2013 Park et al., 2008; Soldner et al., 2009 Cavaliere et al., 2010; Daviaud et al., 2014;…”
BackgroundFanning, S., Haque, A., Imberdis, T., Baru, V., Barrasa, M. I., Nuber, S., Termine, D., Ramalingam, N., Ho, G. P. H., Noble, T., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.028 · Cited by 285
Current status of pluripotent stem cells: moving the first therapies to the clinic
Kimbrel, E. A., & Lanza, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4738 · Cited by 261
Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity
Choi, M. L., Chappard, A., Singh, B. P., Maclachlan, C., Rodrigues, M., Fedotova, E. I., Berezhnov, A. V., De, S., Peddie, C. J., Athauda, D., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01140-3 · Cited by 254
Self-citationiPS cell technologies: significance and applications to CNS regeneration and disease
Okano, H., & Yamanaka, S. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-22 · Cited by 233
Su, Y.-C., & Qi, X. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt301 · Cited by 222
Woodard, C. M., Campos, B. A., Kuo, S.-H., Nirenberg, M. J., Nestor, M. W., Zimmer, M., Mosharov, E. V., Sulzer, D., Zhou, H., Paull, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.023 · Cited by 222
“In postmortem analysis of PD brains with GBA mutations, Lewy bodies are immunoreactive for GBA, suggesting that GBA mutations are sufficient for a-synuclein aggregation (Goker-Alpan et al., 2010). a-synuclein aggregation is a pathological hallmark of PD. Accumulating evidence has identified this phenotype in dopaminer…”
InfluentialProts, I., Grosch, J., Brazdis, R.-M., Simmnacher, K., Veber, V., Havlicek, S., Hannappel, C., Krach, F., Krumbiegel, M., Schütz, O., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713129115 · Cited by 216
Advancement in the modelling and therapeutics of Parkinson’s disease
Rai, S. N., & Singh, P. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101752 · Cited by 213
Kantor, B., Tagliafierro, L., Gu, J., Zamora, M. E., Ilich, E., Grenier, C., Huang, Z. Y., Murphy, S., & Chiba-Falek, O. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.019 · Cited by 204
Chung, S. Y., Kishinevsky, S., Mazzulli, J. R., Graziotto, J., Mrejeru, A., Mosharov, E. V., Puspita, L., Valiulahi, P., Sulzer, D., Milner, T. A., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.012 · Cited by 205
“…previous PD modeling studies in patient-specific iPSC lines were conducted using early generation differentiation protocols, which resulted in variable dopamine (DA) neuron populations in both quality and quantity (Cooper et al., 2012; Devine et al., 2011; Jiang et al., 2012; Nguyen et al., 2011).”
Reverse engineering Lewy bodies: how far have we come and how far can we go?
Fares, M. B., Jagannath, S., & Lashuel, H. A. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-00416-6 · Cited by 206
Reprogramming Cellular Identity for Regenerative Medicine
Cherry, A. B. C., & Daley, G. Q. (2012) · Cell · doi:10.1016/j.cell.2012.02.031 · Cited by 191
Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells
Tran, J., Anastacio, H., & Bardy, C. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0110-8 · Cited by 176
APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons.
Moore, S., Evans, L. D. B., Andersson, T., Portelius, E., Smith, J., Dias, T. B., Saurat, N., McGlade, A., Kirwan, P., Blennow, K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.068 · Cited by 179
“Healthy control cell lines were NDC (Israel et al., 2012), NAS6 (Devine et al., 2011), and the H9 ES (WiCell Research Institute); additional disease lines were APP duplication (Israel et al., 2012) and Ts21 iPSCs (Park et al., 2008).”
MethodSelf-citationCavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
Self-citationOliveira, L. M. A., Falomir-Lockhart, L. J., Botelho, M. G., Lin, K.-H., Wales, P., Koch, J. C., Gerhardt, E., Taschenberger, H., Outeiro, T. F., Lingor, P., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.318 · Cited by 160
Heman-Ackah, S. M., Manzano, R., Hoozemans, J. J., Scheper, W., Flynn, R., Haerty, W., Cowley, S. A., Bassett, A. R., & Wood, M. J. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx331 · Cited by 156
How multi-organ microdevices can help foster drug development
Esch, M. B., Smith, A. S. T., Prot, J.-M., Oleaga, C., Hickman, J. J., & Shuler, M. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.003 · Cited by 153
The many faces of alpha‐synuclein mutations
Kasten, M., & Klein, C. (2013) · Movement Disorders · doi:10.1002/mds.25499 · Cited by 154
Kouroupi, G., Taoufik, E., Vlachos, I. S., Tsioras, K., Antoniou, N., Papastefanaki, F., Chroni-Tzartou, D., Wrasidlo, W., Bohl, D., Stellas, D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617259114 · Cited by 150
Complex Tissue and Disease Modeling using hiPSCs
Passier, R., Orlova, V., & Mummery, C. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.011 · Cited by 142
Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research
Wray, S., Self, M., NINDS Parkinson's Disease iPSC Consortium, NINDS Huntington's Disease iPSC Consortium, NINDS ALS iPSC Consortium, Lewis, P. A., Taanman, J.-W., Ryan, N. S., Mahoney, C. J., Liang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043099 · Cited by 138
Self-citationLogan, S., Arzua, T., Canfield, S. G., Seminary, E. R., Sison, S. L., Ebert, A. D., & Bai, X. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180025 · Cited by 151
Models of α-synuclein aggregation in Parkinson’s disease
Giráldez-Pérez, R. M., Antolín-Vallespín, M., Muñoz, M. D., & Sánchez-Capelo, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0176-9 · Cited by 132
“5 Mb) have been seen to give rise to PD, which has been related to the overexpression of the wild-type protein [43,48], influencing the age of onset and severity of the disorder [49].”
BackgroundChang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H.-L., Chiou, T.-W., Lin, S.-Z., Harn, H.-J., & Ho, T.-J. (2020) · Molecules · doi:10.3390/molecules25082000 · Cited by 133
Domingo, A., & Klein, C. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00014-2 · Cited by 152
Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Stoddard-Bennett, T., & Reijo Pera, R. (2019) · Cells · doi:10.3390/cells8010026 · Cited by 127
Induced Pluripotency and Oncogenic Transformation Are Related Processes
Riggs, J. W., Barrilleaux, B. L., Varlakhanova, N., Bush, K. M., Chan, V., & Knoepfler, P. S. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0375 · Cited by 134
Sabapathy, V., & Kumar, S. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12839 · Cited by 123
Cell Therapy for Parkinson’s Disease
Yasuhara, T., Kameda, M., Sasaki, T., Tajiri, N., & Date, I. (2017) · Cell Transplantation · doi:10.1177/0963689717735411 · Cited by 131
“DAergic neurons from PD patient-derived iPSCs produce double the amount of a-synuclein protein compared to neurons from unaffected donors.(66) A recent study revealed significant differences in gene expression of DAergic neurons derived from iPSCs of PD patients, especially in genes related to neuronal maturity compar…”
ResultLaperle, A., Sances, S., Yucer, N., Dardov, V. J., Garcia, V. J., Ho, R., Fulton, A., Jones, M. R., Roxas, K., Avalos, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0739-1 · Cited by 132
Internalization, axonal transport and release of fibrillar forms of alpha-synuclein
Bieri, G., Gitler, A. D., & Brahic, M. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.007 · Cited by 121
Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages
Haenseler, W., Zambon, F., Lee, H., Vowles, J., Rinaldi, F., Duggal, G., Houlden, H., Gwinn, K., Wray, S., Luk, K. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09362-3 · Cited by 117
Self-citationKwak, T. H., Kang, J. H., Hali, S., Kim, J., Kim, K.-P., Park, C., Lee, J.-H., Ryu, H. K., Na, J. E., Jo, J., et al. (2020) · Stem Cells · doi:10.1002/stem.3163 · Cited by 108
Editing the genome of hiPSC with CRISPR/Cas9: disease models
Bassett, A. R. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9684-9 · Cited by 109
Collo, G., Cavalleri, L., Bono, F., Mora, C., Fedele, S., Invernizzi, R. W., Gennarelli, M., Piovani, G., Kunath, T., Millan, M. J., et al. (2018) · Neural Plasticity · doi:10.1155/2018/4196961 · Cited by 112
“Several laboratories have developed protocols to differentiate hiPSCs into midbrain DA neurons [36, 37].”
Self-citationModeling human neurological disorders with induced pluripotent stem cells
Imaizumi, Y., & Okano, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12625 · Cited by 109
Cellular models to investigate biochemical pathways in Parkinson’s disease
Alberio, T., Lopiano, L., & Fasano, M. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08516.x · Cited by 131
Highly efficient baculovirus-mediated multigene delivery in primary cells
Mansouri, M., Bellon-Echeverria, I., Rizk, A., Ehsaei, Z., Cianciolo Cosentino, C., Silva, C. S., Xie, Y., Boyce, F. M., Davis, M. W., Neuhauss, S. C. F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11529 · Cited by 106
Current status of drug screening and disease modelling in human pluripotent stem cells
Rajamohan, D., Matsa, E., Kalra, S., Crutchley, J., Patel, A., George, V., & Denning, C. (2013) · BioEssays · doi:10.1002/bies.201200053 · Cited by 99
Imaizumi, K., Sone, T., Ibata, K., Fujimori, K., Yuzaki, M., Akamatsu, W., & Okano, H. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.10.005 · Cited by 98
“…Dimos et al., 2008; Egawa et al., 2012), Alzheimer’s disease (AD; Israel et al., 2012; Kondo et al., 2013; Yagi et al., 2011), Parkinson’s disease (Devine et al., 2011; Imaizumi et al., 2012; Nguyen et al., 2011), schizophrenia (Brennand et al., 2011; Bundo et al., 2014; Hook et al., 2014),…”
BackgroundIn vitro bioengineered model of cortical brain tissue
Chwalek, K., Tang-Schomer, M. D., Omenetto, F. G., & Kaplan, D. L. (2015) · Nature Protocols · doi:10.1038/nprot.2015.091 · Cited by 98
Anastasaki, C., Woo, A. S., Messiaen, L. M., & Gutmann, D. H. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv103 · Cited by 94
Prion-like propagation of pathology in Parkinson disease
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63945-5.00017-9 · Cited by 94
Theka, I., Caiazzo, M., Dvoretskova, E., Leo, D., Ungaro, F., Curreli, S., Managò, F., Dell’Anno, M. T., Pezzoli, G., Gainetdinov, R. R., et al. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0133 · Cited by 105
Lin, L., Göke, J., Cukuroglu, E., Dranias, M. R., VanDongen, A. M. J., & Stanton, L. W. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.022 · Cited by 102
Experimental models of Parkinson's disease: Challenges and Opportunities
Lal, R., Singh, A., watts, S., & Chopra, K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176819 · Cited by 95
New lessons learned from disease modeling with induced pluripotent stem cells
Önder, T. T., & Daley, G. Q. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.05.005 · Cited by 97
Chen, Y., Dolt, K. S., Kriek, M., BAKER, T. S., Downey, P. M., Drummond, N. J., Canham, M. A., Natalwala, A., Rosser, S. J., & Kunath, T. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14286 · Cited by 97
“To confirm these results with an independent cell line, we used the same strategy to target exon 2 of the SNCA gene in AST18 iPSCs, which harbour a triplication containing the SNCA locus (Devine et al., 2011).”
MethodSelf-citationTherapeutic Translation of iPSCs for Treating Neurological Disease
Yu, D. X., Marchetto, M. C., & Gage, F. H. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.018 · Cited by 93
Praveena, S. M., Teh, S. W., Rajendran, R. K., Kannan, N., Lin, C., Abdullah, R., & Kumar, S. S. (2018) · Environmental Science and Pollution Research · doi:10.1007/s11356-018-1652-8 · Cited by 90
“…is not limited to the blood disorder; it has been widely used for many other disorder therapies which include retinal disease, spinal cord injury, multiple sclerosis (Siqueira 2011), heart disease (Alaiti et al. 2010), Parkinson’s diseases (Devine et al. 2011), and cancer (Ahmed et al. 2010).”
BackgroundA cell culture model for monitoring α-synuclein cell-to-cell transfer
Reyes, J. F., Olsson, T. T., Lamberts, J. T., Devine, M. J., Kunath, T., & Brundin, P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.003 · Cited by 83
“Briefly, induced pluripotent stem cells (iPSCs) were generated from skin fibroblasts taken from normal individuals (controls) or from patients carrying a triplication of the α-syn gene (Devine et al., 2011).”
BackgroundResultSelf-citationO’Keeffe, G. W., & Sullivan, A. M. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.06.025 · Cited by 97
Yagi, T., Kosakai, A., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Nabetani, A., Ishikawa, F., Arai, Y., Hirose, N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041572 · Cited by 82
Up-regulation of SNCA gene expression: implications to synucleinopathies
Tagliafierro, L., & Chiba‐Falek, O. (2016) · Neurogenetics · doi:10.1007/s10048-016-0478-0 · Cited by 94
“iPSCs with SNCA triplication into dopaminergic neurons [42, 43].”
BackgroundKang, S., Chen, X., Gong, S., Yu, P., Yau, S., Su, Z., Zhou, L., Yu, J., Pan, G., & Shi, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-12452-x · Cited by 93
FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling
Arias, J., Jarazo, J., Qing, X., Walter, J., Gomez‐Giro, G., Nickels, S., Zaehres, H., Schöler, H. R., & Schwamborn, J. C. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.08.026 · Cited by 88
“Patients carrying mutations in the SNCA gene suffer from early onset of PD. Mutations in SNCA include increase in gene dosage (Devine et al., 2011) and heterozygous missense mutations such as p.A30P and p.A53T (Bendor et al., 2013; Soldner et al., 2011).”
BackgroundTargeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Teil, M., Arotçarena, M.-L., Faggiani, E., Laferrière, F., Bézard, E., & Dehay, B. (2020) · Biomolecules · doi:10.3390/biom10030391 · Cited by 85
Heman-Ackah, S. M., Bassett, A. R., & Wood, M. J. A. (2016) · Scientific Reports · doi:10.1038/srep28420 · Cited by 79
Pramanik, S., Sulistio, Y. A., & Heese, K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0214-7 · Cited by 82
PICALM Rescues Endocytic Defects Caused by the Alzheimer’s Disease Risk Factor APOE4
Narayan, P., Sienski, G., Bonner, J. M., Lin, Y.-T., Seo, J., Baru, V., Haque, A., Milo, B., Akay, L. A., Graziosi, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108224 · Cited by 75
Wu, Y.-Y., Chiu, F.-L., Yeh, C.-S., & Kuo, H.-C. (2019) · Open Biology · doi:10.1098/rsob.180177 · Cited by 75
Kramer, A. S., Harvey, A. R., Plant, G. W., & Hodgetts, S. I. (2012) · Cell Transplantation · doi:10.3727/096368912x655208 · Cited by 79
Parkinson's disease in a dish – Using stem cells as a molecular tool
Badger, J. L., Llana, O. C., Hartfield, E. M., & Wade‐Martins, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.035 · Cited by 86
Stem cell therapy for neurological disorders: A focus on aging
Nguyen, H., Zarriello, S., Coats, A. B., Nelson, C., Kingsbury, C., Gorsky, A., Rajani, M., Neal, E. G., & Borlongan, C. V. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.011 · Cited by 80
“However, thanks to the emergence of iPSC techniques, patient-specific models of MSA are currently being used to elucidate the specific pathogenesis of MSA so that targeted treatments thereof may be developed (Abati et al., 2018; Devine et al., 2011).”
BackgroundKim, M. S., Ra, E. A., Kweon, S. H., Seo, B. A., Ko, H. S., Oh, Y., & Lee, G. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.05.015 · Cited by 78
Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations
Kolagar, T. A., Farzaneh, M., Nikkar, N., & Khoshnam, S. E. (2019) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x14666190823142911 · Cited by 74
Induced pluripotent stem cells: a tool for modeling Parkinson’s disease
Bose, A., Petsko, G. A., & Studer, L. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.05.001 · Cited by 76
Bahmad, H. F., Hadadeh, O., Chamaa, F., Cheaito, K. A., Darwish, B., Makkawi, A.-K., & Abou-Kheir, W. G. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00050 · Cited by 76
“This was followed by SHH, WNT1, and Dickkopf WNT signaling pathway inhibitor 1 (Dkk1) blocking antibody treatment for 8 days, then switching the culture conditions to promote maturation of mDA neurons from neural progenitors (Devine et al., 2011).”
BackgroundMethodInfluentialCremades, N., & Dobson, C. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.009 · Cited by 79
“…that the stable αS oligomers are toxic when exposed to neuronal cells (Angelova et al., 2016; Chen et al., 2015; Cremades et al., 2012: Deas et al., 2016) and reproducemost of the pathophysiological features of PD in model neurons (Angelova et al., 2016; Deas et al., 2016; Devine et al., 2011).”
Olgiati, S., Thomas, A., Quadri, M., Breedveld, G. J., Graafland, J., Eussen, H. J., Douben, H., de Klein, A., ONOFRJ, M. C., & Bonifati, V. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.06.005 · Cited by 69
iPSC technology to study human aging and aging-related disorders
Liu, G., Ding, Z., & Belmonte, J. C. I. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.08.014 · Cited by 77
“[54 ].”
BackgroundInfluentialGenetics of Parkinson disease and other movement disorders
Kumar, K. R., Lohmann, K., & Klein, C. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283547627 · Cited by 74
The Role of Glia in Alpha-Synucleinopathies
Fellner, L., & Stefanova, N. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8340-3 · Cited by 68
Recent advances in the applications of iPSC technology
Wiegand, C., & Banerjee, I. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.05.011 · Cited by 75
Engel, M., Do‐Ha, D., Muñoz, S. S., & Ooi, L. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2265-3 · Cited by 76
Metadata
- Authors
- Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., Schapira, A. H., Gwinn, K., Hardy, J., Lewis, P. A., & Kunath, T.
- Affiliations
- MRC Centre for Regenerative Medicine (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Roslin Institute (GB)
- University of Tsukuba (JP)
- Baylor College of Medicine (US)
- Corresponding author
- Devine, Michael J.
- Kunath, Tilo
- ORCID
- Venue
- Nature Communications
- Published
- 2011-08-23
- Volume
- 2
- Issue
- 1
- Pages
- 440-440
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3265381
- OpenAlex
- W1985010554
- Cited by
- 486
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 27 · 2023: 25 · 2022: 40 · 2021: 26 · 2020: 43 · 2019: 24 · 2018: 46 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 29 · 2013: 32 · 2012: 48
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- ASEP (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- University of Dundee
- Wellcome Trust (089698)
- Parkinson's UK (K-0911, G-4046, G-0907, F1002), F-0902)
- Brain Research Trust
- University of Sheffield
- Medical Research Council (MC_G1000735)
- Biotechnology and Biological Sciences Research Council (BBS/E/R/00001627, BBS/E/R/00001601)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, SNCA triplication, familial Parkinson's disease, midbrain dopaminergic neurons, disease modeling, neurodegeneration, multiple system atrophy, dementia with Lewy bodies, alpha-synuclein overexpression
- MeSH terms
- Cell Differentiation, Cells, Cultured, Humans, Neurons, Parkinson Disease, Gene Dosage, alpha-Synuclein, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.